Single application of clotrimazole cream in the management of fungal otitis externa
Open Access
- 1 September 2024
- journal article
- research article
- Published by AME Publishing Company in Australian Journal of Otolaryngology
- Vol. 7, 36
Abstract
Background: Fungal otitis externa (FOE) is a common infection of the external ear canal. FOE is often associated with tympanic membrane perforation (TMP). This may be pre-existing or caused by the infection. The potential risk of ototoxicity from topical medication provides an additional treatment challenge for these patients. In this audit, a comparison is made of outcomes for patients with FOE managed with three different treatments. We compare two topical treatments licensed for use in Australia: flumetasone pivalate/clioquinol ear drops and triamcinolone acetonide/neomycin sulphate/gramicidin/nystatin ointment, with the off-label use of clotrimazole 1% cream. This is to determine if clotrimazole (the only treatment of the three without risk of ototoxicity) is as efficacious as the current licensed treatments. Methods: A review of patients diagnosed with FOE from a single Victorian specialist Ear, Nose and Throat (ENT) hospital Emergency Department (ED) was undertaken. Data from a 6-month period (March 2021–September 2021) were collected. Any patient who had presented to the ED, was subsequently confirmed on microscopy results to have FOE, and was reviewed 2 weeks post-treatment in ENT clinic was included. Successful treatment was defined as no further treatment requirement at the 2-week review. Results: Fifty-eight patients met the inclusion criteria. Ten of 16 patients (63%) were successfully treated with flumetasone pivalate/clioquinol eardrops. Twenty of 30 patients (67%) were successfully treated with triamcinolone acetonide/neomycin sulphate/gramicidin/nystatin ointment. Seven of 12 patients (58%) were successfully treated with clotrimazole 1% cream. There was no statistically significant difference between successful treatment rates between the topical treatments (Chi-square: 0.27, P=0.87). Conclusions: Clotrimazole appears to be as efficacious in the management of FOE as other topical antifungal agents. Although used off-label, it is not associated with ototoxicity. It should be considered an appropriate first-line treatment for patients with FOE, especially in the setting of TMP.Keywords
This publication has 10 references indexed in Scilit:
- Topical azole treatments for otomycosisCochrane Database of Systematic Reviews, 2021
- Oxymetazoline, Mupirocin, Clotrimazole—Safe, Effective, Off-Label Agents for Tympanostomy Tube CareEar, Nose & Throat Journal, 2020
- Diagnosis and treatment of otomycosis in southern ChinaMycoses, 2019
- Otomycosis With Tympanic Membrane Perforation: A Review of the LiteratureEar, Nose & Throat Journal, 2019
- Single Dose Topical Application of Clotrimazole for the Treatment of Otomycosis: Is This Enough?Journal of Audiology and Otology, 2019
- Locacorten Vioform Ototoxicity Upon Guinea Pig Middle Ear ApplicationJournal of Audiology and Otology, 2018
- A comparison of Locacorten‐Vioform and clotrimazole in otomycosis: A systematic review and one‐way meta‐analysisThe Laryngoscope, 2015
- Outcome of 22 cases of perforated tympanic membrane caused by otomycosisThe Journal of Laryngology & Otology, 2001
- Ototoxicity of Common Topical Antimycotic PreparationsThe Laryngoscope, 2000
- Antimykotische Therapie bei Otomykose mit TrommelfelldefektHNO, 2000